llicit drug use continues to be a prevalent and growing problem in the United States, and the use of newer substances is on the rise. Because of the increasing prevalence and tweaking of compounds to avoid detection, the identification of drug abuse by practitioners often relies on signs and symptoms. In this session, presenters reviewed some of these agents, including their history and their impact on those abusing them.
Illicit drug use continues to be a prevalent and growing problem in the United States. Data from the Substance Abuse and Mental Health Services Administration national survey indicate that over the past 6 to 7 years, there has been a notable upswing in “daily or almost daily” marijuana use. “It is thought that this trend is in part due to aging baby boomers, who have not given up the habit, as well as new, younger users in a kind of grandfathered effect,” noted Ernest J. Dole, PharmD, PhC, FASHP, BCPS, of the University of New Mexico Hospital’s Pain Consultation and Treatment Center.
Dr Dole also noted that marijuana use is far more prevalent among persons aged 18 to 25 years. In 2012, 21% in this age group had used marijuana in the past month compared with 7% of persons 26 years and older. Also, marijuana use outweighed the use of cocaine and psychotherapeutics (ie, prescription stimulants).
In addition, the use and abuse of newer substances is becoming more common in the United States. This trend may be driven by changes in the legal status of existing substances of abuse and increased difficulty in obtaining prescription drugs for nonmedical use. These factors are encouraging users to look for options that are “barely legal,” less expensive, more readily available, or have more desirable pharmacologic effects.
In some cases, the primary reason for the use of newer drugs is to avoid detection. Dr Dole noted, “Those who are breaking the law are typically 2 to 3 years ahead of those who obey the law. They often tweak their products just enough to avoid current screening tools, and by the time the tests catch up, the drugs are altered again.” Because of the difficulty in screening and identifying agents, practitioners often have to rely on signs and symptoms to identify drug abuse among patients who present for medical care.
Some of the “barely, but still, legal” drugs are those of herbal origin that, when used in sufficient (and abundant) quantities, produce the desired effects. Individuals who use these products may not realize they are doing something harmful because the products are legal, and the users rationalize that they are “using all-natural things.”
Angela G. Huskey, PharmD, CPE, from the University of Florida College of Pharmacy, continued the discussion by reviewing some of the more commonly abused and recently newsworthy products, such as “bath salts,” more scientifically known as synthetic cannabinoids and synthetic cathinones.
Synthetic cannabinoids (ie, Spice, K2, Yucatan fire, black mamba) were first identified internationally in 2004. Although banned in Europe and Russia in 2010, they made their first appearance in the United States around 2009 to 2010. At the time, they were marketed as a “safe alternative” to marijuana. The active ingredients are commonly sprayed onto other plant materials such as incense, potpourri, and air fresheners.
The effects of synthetic cannabinoids are similar to those of tetrahydrocannabinol, but are commonly exaggerated. They include elevated mood, relaxation, and altered perception, but also tachycardia, paranoia, anxiety, and hallucinations. In some cases, urgent medical care is required. Deaths associated with their use have also been reported. Additionally, some effects are mixed because individuals may experience the effects of the synthetic cannabinoids as well as the herbal products with which they may be used.
Synthetic cathinones (ie, bath salts) are derivatives of cathinone, an active compound from the khat plant. Cathinones are central nervous system stimulants similar in structure to amphetamines. The most common versions are methylone and methylenedioxypyrovalerone.
Cathinones are indirect sympathomimetic agents that enhance the release of and inhibit the reuptake and breakdown of norepinephrine, dopamine, and serotonin. The effects of these compounds are similar to other amphetamine-like medications and include euphoria, heightened alertness, and increased energy as well as hypertension, tachycardia, hyperthermia, dehydration, and psychomotor agitation.
Fortunately, data suggest that exposure to bath salts has diminished significantly since 2011 with the awareness of their abuse and the change in legal status.
Closing the session, Jennifer M. Strickland, PharmD, BCPS, also from the University of Florida College of Pharmacy, presented information about a few other common substances of abuse, including:
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Pediatric Alopecia Areata Risks and Disparities Vary by Race and Ethnicity
October 30th 2024Alopecia areata is more prevalent in Hispanic, Asian/Pacific Islander, and Black children than in non-Hispanic White children, with some Asian subgroups having a higher risk compared with those of Chinese ethnicity.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Studies Highlight Heavy Burden on Caregivers of Patients With DMD
October 28th 2024Caregivers of both adults and children with Duchenne muscular dystrophy (DMD) face significant disruptions to their work productivity and personal lives, underscoring the need for better treatments and support systems.
Read More